Ameritas Investment Company’s Regeneron Pharmaceuticals REGN Stock Holding History

Ameritas Investment Company’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-515	Closed	-$244K	–	1770
2021 Q1	$244K	Buy	+515	New	+$251K	0.02%	518
2020 Q2	–	Sell	-146	Closed	-$72K	–	1308
2020 Q1	$72K	Buy	+146	New	+$60.2K	0.01%	579
2019 Q4	–	Sell	-49	Closed	-$14K	–	1348
2019 Q3	$14K	Buy	+49	New	+$14.5K	﹤0.01%	1040
2019 Q2	–	Sell	-49	Closed	-$20K	–	712
2019 Q1	$20K	Sell	49 -354	-88%	-$146K	﹤0.01%	558
2018 Q4	$151K	Buy	+403	New	+$148K	0.03%	348

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Ameritas Investment Company's REGN Position: Q2 2021 in Review

Ameritas Investment Company sold out of Regeneron Pharmaceuticals (REGN) in Q2 2021, closing a stake of 515 shares — an estimated $244K sold.

Ameritas Investment Company first reported a position in REGN in Q4 2018 and held it in 5 quarters. The position peaked at $244K in Q1 2021. 972 funds tracked by Wall St. Rank hold REGN as of Q2 2021.

Ameritas Investment Company reported no remaining Regeneron Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Ameritas Investment Company sold 515 Regeneron Pharmaceuticals shares in Q2 2021, an estimated $244K.
Ameritas Investment Company first reported a position in Regeneron Pharmaceuticals in Q4 2018 and held it in 5 quarters.
Ameritas Investment Company's Regeneron Pharmaceuticals position peaked at $244K in Q1 2021.
972 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2021.

Based on Ameritas Investment Company's 13F filing for Q2 2021, filed 16 Aug 2021.